新金融搜索:
首页 > 财经 > 财经热点

Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates

发布时间:2019-11-07
Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept
Includes an option for Biogen to extend existing commercialization agreement for Samsung Bioepis’ anti-TNF medicines in Europe
来源:
作者: